Dear Colleagues,

It is with great pleasure that we welcome you to the 31st Annual Scientific Meeting of International Society of Cardiovascular Pharmacotherapy (ISCP), taking place from 3rd to 5th July 2026 in Singapore.

As we gather in this vibrant city, we celebrate not only the science of the heart — but the heart of science. ISCP 2026 brings together clinicians, researchers, and visionaries dedicated to improving cardio-metabolic-renal-liver health across disciplines and borders. Expect an exciting programme of scientific presentations, clinical insights, and meaningful discussions that touch both evidence and empathy.

Singapore, with its dedication to innovations and warmth of hospitality, provides the ideal backdrop to reconnect and collaborate.

We look forward to welcoming you to an inspiring congress experience.

Doreen Tan
Organising Chair
ISCP 2026

Scientific Programme

The programme spans three full days of symposia, debates, keynote lectures and interactive sessions covering the most pressing topics in cardiovascular care:

Heart Failure & Cardiomyopathies Novel therapies matched to patient phenotypes, gene-directed treatments, soluble guanylate cyclase stimulators, CRISPR in cardiovascular medicine, and advanced HF pharmacotherapies beyond quadruple therapy.

Lipid Management From siRNA therapy to real-world outcomes, closing the gap between guidelines and practice, lipid strategies across the ASCVD continuum, and a dedicated 360° approach to lipid management from specialists to primary care.

Cardiometabolic & Kidney Disease Diabetes, kidneys and the heart as a unified therapeutic target; adiposity-based chronic disease across the continuum; GLP-1 RAs and tirzepatide in cardiovascular prevention; CKM risk reduction strategies.

Cardio-Oncology Precision approaches across the cancer treatment continuum — from risk stratification before therapy to survivorship management and long-term cardiovascular risk.

Arrhythmia & Anticoagulation Modern AF detection and stroke prevention, rhythm control strategies, DOACs in complex populations, and a Pro-Con Debate on DAPT vs Ticagrelor monotherapy in 2026.

Hypertension Resistant hypertension mechanisms, precision medicine approaches, pharmacogenomics, and community-based prevention programmes.

Emerging Frontiers AI-nomics and telehealth, digital biomarkers, cardio-geriatrics, pulmonary hypertension, vaccination in cardiovascular disease, and women's heart health.

Highlights

• Neufeld Lecture: Factor XIa anticoagulants — is there finally a free lunch in this world?

• Closing Keynote: Regenerate, Personalise, Prevent

• Pro-Con Debate: DAPT or Ticagrelor monotherapy in 2026 and beyond?

• Breakfast with the Experts: Small-group discussions on Heart Failure, Lipids, CKM, Arrhythmia, Anticoagulation, Clinical Trial Design, and Leadership

• Pre-Congress Workshop: Mastering Scientific Writing in Cardiovascular Pharmacotherapy: From Idea to Publication (2 July 2026 — limited spots)

• Rapid Fire Updates: Oral PCSK9 inhibitors, vericiguat, and pharmacometabolic strategies in AF